SULFAMYLON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sulfamylon, and when can generic versions of Sulfamylon launch?
Sulfamylon is a drug marketed by Rising and Mylan Institutional and is included in two NDAs.
The generic ingredient in SULFAMYLON is mafenide acetate. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mafenide acetate profile page.
Summary for SULFAMYLON
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 105 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,043 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SULFAMYLON |
| What excipients (inactive ingredients) are in SULFAMYLON? | SULFAMYLON excipients list |
| DailyMed Link: | SULFAMYLON at DailyMed |
Recent Clinical Trials for SULFAMYLON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mylan Bertek Pharmaceuticals | Phase 4 |
| Mylan Pharmaceuticals | Phase 4 |
| The University of Texas Medical Branch, Galveston | Phase 2/Phase 3 |
Pharmacology for SULFAMYLON
| Drug Class | Methylated Sulfonamide Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for SULFAMYLON
US Patents and Regulatory Information for SULFAMYLON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rising | SULFAMYLON | mafenide acetate | CREAM;TOPICAL | 016763-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Mylan Institutional | SULFAMYLON | mafenide acetate | FOR SOLUTION;TOPICAL | 019832-003 | Jun 5, 1998 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SULFAMYLON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Rising | SULFAMYLON | mafenide acetate | CREAM;TOPICAL | 016763-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SULFAMYLON
See the table below for patents covering SULFAMYLON around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Netherlands | 6704087 | ⤷ Try a Trial | |
| Belgium | 695694 | ⤷ Try a Trial | |
| United Kingdom | 1145193 | ⤷ Try a Trial | |
| Israel | 27594 | ANTIBACTERIAL COMPOSITIONS CONTAINING P-AMINOMETHYLBENZENESULFONAMIDE SALTS WITH ORGANIC ACIDS | ⤷ Try a Trial |
| France | 6287 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
